Clinical study integrates lifestyle coaching to measure the impact of early detection and coaching on cognitive health using advanced technology platform
Welkin Health, a San Francisco-based company that helps build digital therapeutics on its platform, has partnered with Neurotrack, a digital health company focused on the early detection of cognitive decline and prevention of diseases like Alzheimer’s.
A 6-month clinical study will utilize Welkin Health coaches to support Neurotrack’s cognitive assessment and lifestyle program designed to help individuals at risk for cognitive decline. Welkin’s configurable platform will enable the study team to engage, track and measure cognitive health outcomes of individuals over time to determine the effectiveness of early detection and lifestyle programs using Neurotrack’s technology.
“More than 16 million Americans live with cognitive impairment, and more than five million have Alzheimer’s, with that number expected to grow as baby boomers age,” says Elli Kaplan, CEO and co-founder of Neurotrack. “Changes in lifestyle can alter the course of cognitive decline, improve outcomes, and reduce many of the significant costs associated with cognitive disease. With Welkin’s platform and coaches supporting our study, people will receive the guidance, ongoing support and engagement, to ensure that individuals have the resources necessary to stay with the program and ultimately improve their own health.”
Designed specifically to meet the needs of the study, Welkin’s platform will enable health coaching support through workflow prompts, built-in communication tools, and insights delivered from third-party integrations. Collectively, this will allow the Neurotrack team to monitor a person’s progress and measure health outcomes over the course of the study.
Neurotrack’s Imprint™ Check-Up utilizes a patent-pending eye-tracking technology to determine an individual’s future risk for cognitive decline. Once risk is identified, Neurotrack works to emphasize lifestyle changes such as diet, exercise, sleep, stress management and cognitive training, all shown to have measurable impact on brain function. Neurotrack and Welkin Health, both Rock Health portfolio companies, will receive enrollment and data analytics support from a third Rock Health company, Evidation Health, making this the first three-way collaboration in the portfolio.
“Viable solutions to offset the severe challenges that can come with cognitive decline are greatly needed,” says Chase Hensel, CEO and co-founder, Welkin Health. “Neurotrack’s technology is providing a promising solution by focusing on cognitive decline. We are hopeful that this study will show that coaching integrated with a cognitive health program will have a positive impact, changing the future for those at risk for cognitive decline.”